Clinical trial NCT00256321 (phase 2, status: terminated)
Conditions: gastric carcinoma, gastroesophageal junction carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: oxaliplatin, capecitabine, celecoxib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
Reason stopped: 
    closed due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must have histologically proven, pathologically verified and surgically
             incurable(unresectable, recurrent, or metastatic) gastric/gastroesophageal junction
             carcinoma. Gastric lymphoma and Gastrointestinal stromal tumor(GIST) are ineligible
             for this study. At least 6 unstained paraffin-embedded pathologic specimen slides will
             be required for the COX-2 expression assays.

          -  Patient must have bidimensionally measurable disease as defined below. Measurable
             lesions must be assessed (by physical examination, CT scan, radionuclide scan or plain
             X-ray) within 30 days prior to registration. The patient's disease status must be
             completely assessed and reported.

        (Measurable Disease: Bidimensionally measurable lesions with clearly defined margins by: 1)
        Ruler measurement or medical photograph (skin or oral lesion), or plain x ray with at least
        one diameter .5 cm or greater (bone lesions are not included) or, 2) CT, MRI or other
        imaging scan with both diameters greater than the distance between cuts of the imaging
        study, or 3) palpation with both diameters 2 cm or greater.)

          -  All patients must undergo a CT of abdomen and chest within 30 days prior to
             registration.

          -  Patients may have received prior radiation therapy. Radiation therapy must have been
             completed at least 30 days before registration.

          -  Patients may have received prior surgery. Prior surgery must have been completed at
             least 30 days before registration.

          -  Performance status must be 0-2 according to Southwest Oncology Group Criteria

        Exclusion criteria:

          -  Patients with brain metastases are NOT eligible for this study. It is not mandatory to
             obtain brain CT or MRI on all patients. However, patients who exhibit neurological
             symptoms or have pulmonary metastases on radiographic studies must obtain brain CT w/
             IV contrast or MRI prior to registration to ascertain the presence of brain
             metastasis.

          -  Patients must NOT have received capecitabine or oxaliplatin. Prior use of cisplatin,
             carboplatin, 5-FU are permitted. Prior systemic therapy must have been completed at
             least 30 days before registration.

          -  Pregnant or nursing women are not eligible to participate in this trial because the
             safe use of these drugs in pregnancy have not been established. Urine pregnancy test
             must be done prior to the study.

          -  Patient must NOT have known allergic reaction to sulfonamides

          -  Patient must NOT have known allergic or other adverse reaction to celecoxib

          -  Patient must NOT have persistent peripheral neuropathy

          -  Patient must NOT have known hypersensitivity reactions to 5-FU or platinum

          -  Patient must NOT have active gastric/duodenal bleeding

          -  Patient must NOT have had a sensitivity reaction to aspirin or other NSAIDS
             nonsteroidal antiinflammatory drugs (NSAIDS) [experiencing asthma, urticaria, or
             allergic-type reactions after taking aspirin or other NSAIDs]